Search

everythinglearnresearchcommunity

for

Search:↓

Ruxolitinib helped a patient with alopecia areata regrow hair.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Blocking DPP4 can help activate hair growth and improve hair regeneration.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A form of vitamin E promotes hair growth by activating a specific skin pathway.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

SETDB1 is essential for controlling DNA methylation, silencing retrotransposons, and maintaining skin cell health, with its absence leading to skin inflammation and hair loss.

ODC overexpression in hair cells increases tumor growth by reducing Notch signaling.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Cold Atmospheric Microwave Plasma (CAMP) helps hair cells grow and could potentially treat hair loss.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Safflower extract helps protect hair follicle cells from damage caused by chemotherapy.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

Boosting certain cell signals can prevent hair loss from cancer treatments.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.